Petz L D, Calhoun L, Yam P, Cecka M, Schiller G, Faitlowicz A R, Herron R, Sayah D, Wallace R B, Belldegrun A
Department of Pathology and Laboratory Medicine, University of California Los Angeles.
Transfusion. 1993 Sep;33(9):742-50. doi: 10.1046/j.1537-2995.1993.33994025025.x.
A patient without evident immune deficiency who received a transfusion of blood from a second-degree family member developed fatal transfusion-associated graft-versus-host disease (TA-GVHD). The donor was homozygous for an HLA haplotype for which the recipient was heterozygous (one-way HLA match). All 39 reported cases of TA-GVHD in immunocompetent patients were reviewed to ascertain the predisposing factors and to define the indications for irradiating blood for this population. HLA typing was described in 15 cases; in 13, including seven related and six unrelated donors, a one-way HLA match was present. Thirty-one (79%) of the 39 cases were reported from Japan (and 196 other cases are cited in the Japanese literature), but a one-way HLA match among unrelated donors at HLA-A, -B, -DR loci is only approximately two to four times more likely in Japanese persons than in whites. Fresh blood (< 96 hours old) was used in 29 (94%) of the 31 cases reported from Japan and in 33 (87%) of 38 cases overall (in one case, the age of the blood used was not reported). Thus, factors that appear to predispose to TA-GVHD in immunocompetent patients are a one-way HLA match, fresh blood, and, possibly, Japanese ancestry. Irradiating cellular blood components from all blood relatives of transfusion recipients will not completely eliminate the risk of TA-GVHD.
一名无明显免疫缺陷的患者接受了来自二级亲属的输血后,发生了致命的输血相关移植物抗宿主病(TA-GVHD)。供者的HLA单倍型为纯合子,而受者为杂合子(单向HLA匹配)。对39例免疫功能正常患者发生TA-GVHD的报道病例进行了回顾,以确定易感因素,并明确该人群血液辐照的指征。其中15例描述了HLA分型;在13例中,包括7例亲属供者和6例非亲属供者,存在单向HLA匹配。39例病例中有31例(79%)来自日本(日本文献中还引用了另外196例),但在日本人群中,非亲属供者在HLA-A、-B、-DR位点的单向HLA匹配仅比白人高约两到四倍。日本报道的31例病例中有29例(94%)使用了新鲜血液(<96小时),总体38例病例中有33例(87%)使用了新鲜血液(其中1例未报告所使用血液的保存时间)。因此,免疫功能正常患者中似乎易发生TA-GVHD的因素包括单向HLA匹配、新鲜血液,可能还有日本血统。对输血受者所有血亲的细胞血液成分进行辐照并不能完全消除TA-GVHD的风险。